HomeInsightsStock Comparison

Glenmark Pharmaceuticals Ltd vs Lyka Labs Ltd Stock Comparison

Glenmark Pharmaceuticals Ltd vs Lyka Labs Ltd Stock Comparison

Last Updated on: Jul 22, 2025

Key Highlights

  • The Latest Trading Price of Glenmark Pharmaceuticals Ltd is ₹ 2157 as of 22 Jul 15:30.
  • The P/E Ratio of Glenmark Pharmaceuticals Ltd changed from 7.5 on March 2020 to 0 on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Lyka Labs Ltd changed from 10 on March 2022 to 45.1 on March 2025 . This represents a CAGR of 45.73% over 4 years.
  • The Market Cap of Glenmark Pharmaceuticals Ltd changed from ₹ 5814 crore on March 2020 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Lyka Labs Ltd changed from ₹ 36.58 crore on March 2020 to ₹ 360.29 crore on March 2025 . This represents a CAGR of 46.41% over 6 years.
  • The revenue of Glenmark Pharmaceuticals Ltd for the Mar '25 is ₹ 3267 crore as compare to the Dec '24 revenue of ₹ 3418 crore. This represent the decline of -4.41% The revenue of Lyka Labs Ltd for the Mar '25 is ₹ 34.25 crore as compare to the Dec '24 revenue of ₹ 34.62 crore. This represent the decline of -1.07%.
  • The ebitda of Glenmark Pharmaceuticals Ltd for the Mar '25 is ₹ 199.89 crore as compare to the Dec '24 ebitda of ₹ 631.36 crore. This represent the decline of -68.34% The ebitda of Lyka Labs Ltd for the Mar '25 is ₹ 4.9 crore as compare to the Dec '24 ebitda of ₹ 6.02 crore. This represent the decline of -18.6%.
  • The net profit of Glenmark Pharmaceuticals Ltd changed from ₹ 173.13 crore to ₹ 4.38 crore over 8 quarters. This represents a CAGR of -84.09% The net profit of Lyka Labs Ltd changed from ₹ -1.85 crore to ₹ 2.03 crore over 8 quarters. This represents a CAGR of NaN% .
  • The Dividend Payout of Glenmark Pharmaceuticals Ltd changed from 5.21 % on March 2020 to 0 % on March 2025 . This represents a CAGR of -100.00% over 6 yearsThe Dividend Payout of Lyka Labs Ltd changed from 0 % on March 2020 to 0 % on March 2025 . This represents a CAGR of 0.0% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Glenmark Pharmaceuticals Ltd

  • Glenmark Pharmaceuticals Limited was incorporated on November 18, 1977.
  • The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).
  • It is engaged in the business of development, manufacture and marketing of pharmaceutical products both formulation and active pharmaceuticals ingredients to regulated and semi-regulated markets.
  • The Company's research and development facilities are located at Mahape, Sinnar and Taloja and manufacturing facilities are located at Nasik, Colvale, Baddi, Nalagarh, Sikkim, Indore and Aurangabad in India. The company has several molecules in various stages of pre-clinical and clinical development primarily focused in the areas of Oncology, Respiratory and Dermatology.
  • Its branded generics business has a significant presence in markets across emerging economies including India.

About Lyka Labs Ltd

  • Initially manufacturing formulations, Lyka Labs Limited brought bulk drugs into its operational fold by amalgamating Lyphin Chemicals Pvt Ltd with itself in Apr. '83.
  • It also added a range of ayurvedic and animal health care products over the years.
  • In 1990, it diversified into marketing medical and diagnostic equipment and instruments of Bekton Dickinson, US; Airsep Corporation, US; Coloplast, Denmark; and Terumo Corporation, Japan.
  • Lyka Exports is the subsidiary of the company.
  • The Company is engaged in the business of pharmaceutical and related activities, including research. The company offers a broad range of antibiotics used as life-savers and to treat minor infections.

Glenmark Pharmaceuticals Ltd News Hub

News

Glenmark Pharmaceuticals Ltd up for five straight sessions

Glenmark Pharmaceuticals Ltd rose for a fifth straight session today. The stock is quoting...

Read more

16 Jul 2025 13:00

News

Glenmark Pharma receives warning letter from USFDA for Indore facility

The USFDA inspection was conducted between 3 February and 14 February 2025. In an official...

Read more

14 Jul 2025 10:08

News

Glenmark Pharmaceuticals Ltd up for third consecutive session

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quotin...

Read more

14 Jul 2025 13:05

News

Glenmark Pharma soars on AbbVie licensing deal for cancer therapy ISB 2001

The announcement follows a major licensing agreement with U.S. biopharma giant AbbVie. Und...

Read more

11 Jul 2025 11:54

News

Glenmark Pharmaceuticals Ltd leads gainers in 'A' group

Netweb Technologies India Ltd, Globus Spirits Ltd, VST Industries Ltd and Jaiprakash Power...

Read more

11 Jul 2025 12:00

News

IGI Therapeutics SA and AbbVie enter into an exclusive licensing agreement for ISB 2001

IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovatio...

Read more

10 Jul 2025 19:51

Lyka Labs Ltd News Hub

News

Lyka Labs to discuss results

Lyka Labs will hold a meeting of the Board of Directors of the Company on 1 August 2025. P...

Read more

22 Jul 2025 10:53

News

Lyka Labs to conduct AGM

Lyka Labs announced that the 46th Annual General Meeting(AGM) of the company will be held ...

Read more

09 Jul 2025 10:25

News

Lyka Labs to discuss results

Lyka Labs will hold a meeting of the Board of Directors of the Company on 26 May 2025. Pow...

Read more

15 May 2025 11:52

News

Lyka Labs EGM scheduled

Lyka Labs announced that an Extra Ordinary General Meeting (EGM) of the Company will be he...

Read more

01 Feb 2025 13:50

News

Lyka Labs announces board meeting date

Lyka Labs will hold a meeting of the Board of Directors of the Company on 4 February 2025....

Read more

03 Jan 2025 09:46

News

Lyka Labs to declare Quarterly Result

Lyka Labs will hold a meeting of the Board of Directors of the Company on 4 February 2025....

Read more

30 Dec 2024 18:47

SWOT Analysis Of Lyka Labs Ltd

Strength

1

S

Weakness

4

W

Opportunity

1

O

Threats

1

T

SWOT Analysis Of Glenmark Pharmaceuticals Ltd

Strength

4

S

Weakness

2

W

Opportunity

1

O

Threats

1

T

BlinkX Score for Lyka Labs Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Glenmark Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Glenmark Pharmaceuticals Ltd and Lyka Labs Ltd

Which company has a larger market capitalization, Glenmark Pharmaceuticals Ltd or Lyka Labs Ltd?

Market cap of Glenmark Pharmaceuticals Ltd is 60,894 Cr while Market cap of Lyka Labs Ltd is 405 Cr

What are the key factors driving the stock performance of Glenmark Pharmaceuticals Ltd and Lyka Labs Ltd?

The stock performance of Glenmark Pharmaceuticals Ltd and Lyka Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glenmark Pharmaceuticals Ltd and Lyka Labs Ltd?

As of July 22, 2025, the Glenmark Pharmaceuticals Ltd stock price is INR ₹2157.85. On the other hand, Lyka Labs Ltd stock price is INR ₹113.6.

How do dividend payouts of Glenmark Pharmaceuticals Ltd and Lyka Labs Ltd compare?

To compare the dividend payouts of Glenmark Pharmaceuticals Ltd and Lyka Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions